# Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

> **NCT06043427** · PHASE2 · RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 168 (estimated)

## Conditions studied

- Gastroesophageal Adenocarcinoma

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Ramucirumab
- **DRUG:** Zanidatamab

## Key facts

- **NCT ID:** NCT06043427
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2026-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06043427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06043427, "Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT06043427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*